BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38084873)

  • 1. GK921, a transglutaminase inhibitor, strengthens the antitumor effect of cisplatin on pancreatic cancer cells by inhibiting epithelial-to-mesenchymal transition.
    Li M; Wang X; Chen X; Hong J; Du Y; Song D
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166925. PubMed ID: 38084873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
    Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
    Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
    Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
    Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
    Ge X; Jiang Y; Hu X; Yu X
    Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.
    Zhang P; Liu H; Xia F; Zhang QW; Zhang YY; Zhao Q; Chao ZH; Jiang ZW; Jiang CC
    Int J Mol Med; 2014 Jan; 33(1):151-9. PubMed ID: 24173500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.
    Liu Y; Liu L; Mou ZX
    Biochem Genet; 2022 Feb; 60(1):173-190. PubMed ID: 34143331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.
    Wang Y; Yang B; Zhao J; Yu X; Liu X; Zhang L; Zhang Y; Li X; Zhai Z
    Mol Med Rep; 2019 Mar; 19(3):1501-1508. PubMed ID: 30628686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HEY1-mediated cisplatin resistance in lung adenocarcinoma via epithelial-mesenchymal transition.
    Gao J; Li Y; Zou X; Lei T; Xu T; Chen Y; Wang Z
    Med Oncol; 2022 Nov; 40(1):18. PubMed ID: 36396748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
    Cui Z; Li D; Zhao J; Chen K
    Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.
    Wang M; Zhang R; Zhang S; Xu R; Yang Q
    Gene; 2019 Jun; 700():110-119. PubMed ID: 30917930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SATB1 Knockdown Inhibits Proliferation and Invasion and Decreases Chemoradiation Resistance in Nasopharyngeal Carcinoma Cells by Reversing EMT and Suppressing MMP-9.
    Zhou D; Ye C; Pan Z; Deng Y
    Int J Med Sci; 2021; 18(1):42-52. PubMed ID: 33390772
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
    Chen Y; Wang L; Zhou J
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.
    Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS
    BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.